Editorial: Peptidases as a therapeutic target in anti-cancer management
- PMID: 38666021
- PMCID: PMC11043600
- DOI: 10.3389/fphar.2024.1394018
Editorial: Peptidases as a therapeutic target in anti-cancer management
Keywords: ADAM17; anti-tumor treatment; cancer; cathepsins; peptidases; sentrin specific-protease; ubiquitin specific protease.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Peptidases as a therapeutic target in anti-cancer management
References
-
- Barelle C., Porter A. (2015). VNARs: an ancient and unique repertoire of molecules that deliver small, soluble, stable and high affinity binders of proteins. Antibodies 4, 240–258. 10.3390/antib4030240 - DOI
-
- Rawlings N. D., Barrett A. J., Thomas P. D., Huang X., Bateman A., Finn R. D. (2018). The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res. 46, D624–D632. 10.1093/nar/gkx1134 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous